EFFECT OF COTRIMOXAZOLE PROPHYLAXIS IN HIV-1 INFECTED PATIENTS ATTENDING JOS UNIVERSITY TEACHING HOSPITAL

dc.contributor.authorK. D. Falang
dc.contributor.authorN. S. Jimam
dc.contributor.authorJ. Idoko
dc.contributor.authorM. O. Uguru
dc.date.accessioned2026-02-23T11:34:01Z
dc.date.issued2011
dc.description.abstractMany chemo prophylactic approaches to manage or prevent opportunistic infections using many drugs have been reported. Based on the reported cases of chemo prophylactic approaches to manage opportunistic infections, the effect of Cotrimoxazole on HIV patients was studied. Seventy two patients with CD4+ cell counts ≤ 350cells/µl were recruited for the study. Each patient received cotrimoxazole two single strength tablets (2 x 480mg) three times a week. The patients were followed for a period of six months during which time data was collected at month 1, month 3 and month 6. The results showed that dermatological, gastrointestinal and respiratory as well as other bacterial related infections were considerably reduced in these patients during the six month period of the study. Being a drug that is cheap, readily available and not requiring any special storage and handling conditions, cotrimoxazole could be considered as a good prophylactic agent in the management of HIV/AIDS disease in resource limited settings such as ours.
dc.identifier.issn0975-8232
dc.identifier.urihttps://irepos.unijos.edu.ng/handle/123456789/11314
dc.language.isoen
dc.publisherIJPSR
dc.relation.ispartofseriesvol. 2; 4
dc.subjectHIV-1
dc.subjectOpportunistic infection
dc.subjectPatients
dc.subjectCotrimoxazole
dc.subjectProphylaxi
dc.titleEFFECT OF COTRIMOXAZOLE PROPHYLAXIS IN HIV-1 INFECTED PATIENTS ATTENDING JOS UNIVERSITY TEACHING HOSPITAL
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
42-Vol.-2Issue-4IJPSR2011Paper-322.pdf
Size:
380.91 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description: